Category Events

June,2023

NanoMedSyn will participate to the International Symposium on Inorganic  and Environmental Materials ISIEM2023 in Montpellier, France. The symposium will focus on the newest research and technologies on inorganic materials : Nanomaterials, Biomaterials, Functional Materials… https://isiem2023.sciencesconf.org

June, 2023

Join us at Paris Saclay B2B on June, the 1st and 2nd. https://paris-saclay-spring.com/programme-paris-saclay-spring/

March 20-22th, 2023

We will be present at BIO-Europe Spring for one-to-one meeting. https://informaconnect.com/bioeurope-spring/

November, 2022

The 3rd Immune-Oncology World Congress Immuno-Oncology2022 will focus on the latest developments and findings in immuno-oncology therapy as well as targeted therapy. The Congress will examine treatments available on the market as well as treatments still in the development stage. A poster of our work will be on display for the duration of the Congress.  

October, 2022

Immunology, looking to the future of medical sciences. The Thematic Meeting: « Immunology, looking to the future of medical sciences » is a major event for the immunology sector in the south of France. http://fr.ap-hm.fr/sites/default/files/files/221011_%20Programme%20-%20%20Immunology,%20looking%20to%20the%20future%20of%20medical%20science.pdf

October,2022

Day of the cluster : Biotherapy Innovation Occitanie October 13, 2022 in Montpellier https://www.agence-adocc.com/biotherapie-innovation-occitanie/  

June, 2022

NanoMedSyn is co-organiser of  the 2nd Symposium on delivery and target for pediatric tumors, on 23-24th June in Switzerland (Schwarzsee). Our collaborative work and of the company have been presented.

June, 2022

10th Antibody Industrial Symposium 2022 We are proud to announce our participation to the 10th Antibody Industrial Symposium 2022 (AIS2022) that will be held from 28th to 29th June 2022 in person in Montpellier, France. https://aiscongress.com  

October, 2021

NanoMedSyn is classified as a DEEPTECH company by Bpifrance for its Innovative Therapeutic Targeting Technology.

Next Page → ← Previous Page